MedTrace Logo

Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT03559348 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-07-29

No results posted yet for this study

Summary

Multiple centers, uncontrolled, open-label, non-randomized single-arm study

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DRUG

chemotherapy: TS-1, Leucovorin and Gemcitabine

Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Kaohsiung Medical University

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2020-04-20
Completion
2020-04-20

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559348 on ClinicalTrials.gov